Skip to Main Content
Sangeetha Reddy, M.D.

Sangeetha Reddy, M.D.

Titles and Appointments

Associate Professor

Schools
Medical School | Graduate School
Departments
Internal Medicine
Graduate Programs
Cancer Biology, Immunology

You have reached the Academic Profile.

For more information on the doctor and patient care, please visit the clinical profile.

  • Biography

    Sangeetha Reddy, M.D., M.Sc., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology.

    Originally from Baltimore, Dr. Reddy holds a bachelor's degree in biochemical sciences from Harvard University in Cambridge, Massachusetts. She earned her medical degree at the University of California Los Angeles Geffen School of Medicine. She completed internal medicine residency training at McGaw Medical Center of Northwestern University in Chicago, followed by a master's degree in clinical science. She then completed advanced training through a fellowship in medical hematology and oncology at The University of Texas MD Anderson Cancer Center in Houston.

    Dr. Reddy joined the UT Southwestern faculty in 2019. Dr. Reddy's clinical interests include metastatic disease, triple-negative breast cancer, inflammatory breast cancer, and pregnancy-associated breast cancer. Dr. Reddy has been selected as a Cancer Prevention and Research Institute of Texas Recruitment Award recipient and also a Disease-Oriented Clinical Scholar to support her breast cancer research efforts.

  • Education
    Medical Education
    David Geffen School of Medicine at UCLA (2010)
    Residency
    McGaw Medical Center of Northwestern University (2013), Internal Medicine
    Residency
    McGaw Medical Center of Northwestern University (2014), Internal Medicine
    Fellowship
    UT MD Anderson Cancer Center (2017), Hematology Oncology
  • Research Interest
    • Breast Cancer (Especially High Risk Cancers)
    • Cancer Immunotherapy
    • Clinical Trials and Translational Research
    • Tumor Microenvironment
  • Publications
    Restoration of tumor vascular integrity by P188 improves chemotherapy and immunotherapy efficacy in triple negative breast cancer
    Alsup AM, Maksimos M, Fayyaz E, Muruganantham Y, Grubbs M, Al-Noubani M, Arsalani S, Bhattacharyya T, Liu YC, Asare O, Azab F, Nguyen TN, Reddy SM, Cho M, Azab AK Biomedicine and Pharmacotherapy 2026 Oct 203
    Optimized Detection of Left Ventricular Hyperpolarized [1-13C]Pyruvate Signal in Human Cardiac Metabolic Imaging
    Author Collaboration CT, Khashami F, Dimitrov IE, Fuetterer M, Glöggler S, Zhang B, Tan E, Kozerke S, Henning A, Hussain T, Malloy CR, Unni N, Zaha VG, Cantanelli S, Chan I, Cole S, Conzen S, Delgado G, Farr D, Gruber J, Haley B, Klemow D, Li J, McArthur H, Mallik A, Manohar P, Patel I, Peswani N, Reddy S, Sadeghi N, Syed S Magnetic resonance in medicine 2026 Jul 96 420-434
    Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen
    Albert R, Thomas J, Sadeghi N, Reddy SM, Ramos GD, McArthur H, Syed S, Farr D, Unni N Breast Cancer Research and Treatment 2026 Jun 217
    HIF-2–Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma
    Mal A, Xie B, Gray Z, Small C, Ramanand SG, Gao Y, Tcheuyap VT, Debnath S, Christie A, Miyata J, Jackson B, Zhong H, Gao B, Lohrey J, Maalouf NM, Reddy SM, Minna JD, Pedrosa I, Sun X, Mani RS, Kapur P, Brugarolas J Cancer discovery 2025 Dec 15 2485-2504
    Correction: Editor’s Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade (Cancer Discov, (2016), 6, (827–837))
    Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA Cancer discovery 2025 Dec 15 2574
    A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study
    Chang HL, Cao M, Lim M, Moscowitz A, Gao A, Weiss A, Brown A, Spanbauer D, Uwera G, Oh J, Ladner J, Wu N, Okanlawon P, Olivo R, Iyer R, Engidaw Y, Reddy SM, McArthur HL, Xu L, Mohta S, Maues J, Hodgdon C, Chinea L, Lei K, Huang SP, Bansal R, Chan IS Communications Medicine 2025 Dec 5
    Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
    Barroso-Sousa R, Zanudo JG, Li T, Reddy SM, Emens LA, Kuntz TM, Silva CA, AlDubayan SH, Chu H, Overmoyer B, Lange P, DiLullo MK, Montesion M, Kasparian J, Hughes ME, Attaya V, Basta A, Lin NU, Tayob N, Jeselsohn R, Mittendorf EA, Tolaney SM Nature communications 2025 Dec 16
    A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response
    Xu L, Saunders K, Huang SP, Knutsdottir H, Martinez-Algarin K, Terrazas I, Chen K, McArthur HM, Maués J, Hodgdon C, Reddy SM, Roussos Torres ET, Xu L, Chan IS Cell Reports Medicine 2024 May 5
    Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneity
    Lake KE, Colonnetta MM, Smith CA, Saunders K, Martinez-Algarin K, Mohta S, Pena J, McArthur HL, Reddy SM, Roussos Torres ET, Chen EH, Chan IS Frontiers in Cell and Developmental Biology 2024 12
    Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
    Kumar A, Ramani V, Bharti V, De Lima Bellan D, Saleh N, Uzhachenko R, Shen C, Arteaga C, Richmond A, Reddy SM, Vilgelm A Journal for ImmunoTherapy of Cancer 2023 May 11